Harvard Apparatus Regenerative Technology Inc

For the period ended Mar 31, 2024. Filed May 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 13, 2024

HRGNStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and par value data)

	March 31,	December 31,
	2024	2023
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$272	$432
Accounts receivable	7	4
Inventory	44	50
Prepaid research and development	159	210
Prepaid expenses and other current assets	135	87
Total current assets	617	783
Property, plant and equipment, net	19	25
Right-of-use assets, net	21	48
Deferred financing costs	544	544
Long-term prepaid contracts	1,214	1,214
Total assets	$2,415	$2,614
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$890	$445
Accrued and other current liabilities	528	475
Advance from private placement	301	—
Convertible debt – related party	500	—
Operating lease liability	21	48
Total current liabilities	2,240	968
Commitments and contingencies (Note 7)	-	-
Stockholders’ equity:
Common stock, par value $0.01 per share, 60,000,000 shares authorized; 13,947,324 issued and outstanding at March 31, 2024 and December 31, 2023, respectively	139	139
Additional paid-in capital	94,023	93,463
Accumulated deficit	(93,986)	(91,956)
Accumulated other comprehensive loss	(1)	—
Total stockholders’ equity	175	1,646
Total liabilities and stockholders’ equity	$2,415	$2,614

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.